Display Settings:

Format

Send to:

Choose Destination
    Arthritis Res Ther. 2010;12(4):138. Epub 2010 Aug 26.

    A new tool for detection of type I interferon activation in systemic lupus erythematosus.

    Abstract

    The IFN-I pathway is activated in systemic lupus erythematosus (SLE) and appears to be important in the pathogenesis of the disease. As a result, several clinical trials of anti-IFN monoclonal antibodies, which hold promise to control the disease, have been launched. Additionally, activation of IFN-I might be important in the prognosis and activity assessment of the disease. Therefore, new biomarkers that reflect activity of the IFN-I pathway and are simple to measure, such as the monocyte CD64 receptor, are expected to have a great impact on the management of SLE, if properly validated.

    PMID:
    20815919
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2945060
    Free PMC Article

      Supplemental Content

      Icon for BioMed Central Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk